Spartan Wealth Advisory Services LLC Takes Position in Kestra Medical Technologies, Ltd. $KMTS

Spartan Wealth Advisory Services LLC bought a new position in Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 30,268 shares of the company’s stock, valued at approximately $603,000. Spartan Wealth Advisory Services LLC owned approximately 0.05% of Kestra Medical Technologies at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of KMTS. Russell Investments Group Ltd. raised its position in Kestra Medical Technologies by 43.5% in the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock valued at $41,000 after purchasing an additional 474 shares during the last quarter. Brown Brothers Harriman & Co. grew its holdings in shares of Kestra Medical Technologies by 26.8% during the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock worth $74,000 after purchasing an additional 656 shares during the last quarter. Rhumbline Advisers increased its stake in shares of Kestra Medical Technologies by 7.3% in the third quarter. Rhumbline Advisers now owns 12,925 shares of the company’s stock valued at $307,000 after buying an additional 874 shares in the last quarter. Farther Finance Advisors LLC bought a new position in shares of Kestra Medical Technologies in the fourth quarter valued at about $31,000. Finally, Police & Firemen s Retirement System of New Jersey raised its holdings in shares of Kestra Medical Technologies by 34.6% in the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 5,420 shares of the company’s stock valued at $144,000 after buying an additional 1,392 shares during the last quarter.

Insider Activity

In other news, insider Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $20.81, for a total transaction of $312,150.00. Following the completion of the sale, the insider owned 395,467 shares in the company, valued at $8,229,668.27. The trade was a 3.65% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 3.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on KMTS shares. Wall Street Zen lowered shares of Kestra Medical Technologies from a “hold” rating to a “sell” rating in a report on Saturday. Wolfe Research set a $30.00 target price on shares of Kestra Medical Technologies in a research note on Wednesday. Weiss Ratings lowered shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday. BTIG Research increased their price target on shares of Kestra Medical Technologies from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Finally, The Goldman Sachs Group dropped their price objective on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $27.83.

Kestra Medical Technologies Price Performance

Kestra Medical Technologies stock opened at $24.42 on Monday. The business’s 50-day simple moving average is $22.28 and its 200 day simple moving average is $22.69. The stock has a market cap of $1.43 billion, a price-to-earnings ratio of -10.09 and a beta of 0.47. Kestra Medical Technologies, Ltd. has a 12-month low of $14.10 and a 12-month high of $30.00. The company has a quick ratio of 4.41, a current ratio of 4.41 and a debt-to-equity ratio of 0.16.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings data on Tuesday, July 14th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%.The firm had revenue of $28.64 million during the quarter. As a group, research analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.3 earnings per share for the current year.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.